AAIC25: Cognito neuromodulation therapy slows decline in Alzheimer’s disease
Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.
29 July 2025
Cognito’s OVERTURE trial demonstrated significant ‘time saved’ in functional and cognitive decline at both six and 18 months.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.